Validation and Application of a Module of the M. D. Anderson Symptom Inventory for Measuring Multiple Symptoms in Patients With Gastrointestinal Cancer (the MDASI-GI)

被引:98
|
作者
Wang, Xin Shelley [1 ]
Williams, Loretta A. [1 ]
Eng, Cathy [2 ]
Mendoza, Tito R. [1 ]
Shah, Nyma A. [1 ]
Kirkendoll, Karyn J. [1 ]
Shah, Pankil K. [1 ]
Trask, Peter C. [3 ]
Palos, Guadalupe R. [1 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[3] Pfizer Inc, Global Outcomes Res, New London, CT USA
关键词
cancer; symptoms; assessment; validation; gastrointestinal; M. D. Anderson Symptom Inventory; REPORTED OUTCOMES; INSTRUMENT; DISTRESS; PREVALENCE; BURDEN;
D O I
10.1002/cncr.24920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The M. D. Anderson Symptom Inventory (MDASI) was developed as a brief yet comprehensive tool to assess patient-reported symptom severity and interference in patients with cancer. The authors report the development of an MDASI module for use in patients with gastrointestinal (GI) cancer (the MDASI-GI). METHODS: Patients with GI cancer (N = 184) participated in module development and validation. The process included: 1) generating GI-specific candidate items with input from GI oncologists and from qualitative interviews with patients and adding those items to the core MDASI for testing; 2) dropping candidate GI items that lacked sensitivity; 3) validating the psychometric properties (validity, reliability, sensitivity) of the resulting MDASI-GI; and 4) conducting cognitive debriefing interviews with patients to confirm the questionnaire's ease of comprehension, relevance, and acceptability. RESULTS: Five GI-specific symptom items (constipation, diarrhea, difficulty swallowing, change in taste, and feeling bloated) were added to the original 19 MDASI symptom and interference items to form the MDASI-GI. Sixty-one percent of the sample had 1 or more moderate-to-severe symptom(s) (>= 5 on a severity scale from 0 to 10). Cronbach a values were .80 and .87 for symptom severity items and interference items, respectively. Known-group validity (sensitivity) was supported by the ability of the MDASI-GI to detect significant differences in symptom and interference levels according to performance status (P < .001). Cognitive debriefing demonstrated that for patients, the MDASI-GI was an easy-to-use and understandable tool. CONCLUSIONS: The current results indicated that the MDASI-GI is a valid, reliable, and concise tool for measuring symptom severity and interference with function in patients with GI cancer. Cancer 2010;116:2053-63. (c) 2010 American Cancer Society.
引用
收藏
页码:2053 / 2063
页数:11
相关论文
共 50 条
  • [41] Validation of Portuguese version of the MD Anderson Symptom Inventory (MDASI) for patients with head and neck cancer.
    Castro, Ana Filipa Martins Ferreira
    Febra, Joana
    Amorim, Andreina
    Coelho, Andreia Machado
    De Araujo, Alexandra Vieira
    Ferreira, Maria Gloria
    Araujo, Antonio M. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting
    Kamal, Mona
    Navai, Neema
    Bree, Kelly K.
    Williams, Loretta A.
    Cleeland, Charles S.
    Shen, Shu-En
    Wang, Xin Shelley
    [J]. CANCERS, 2022, 14 (16)
  • [43] Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia
    Gabrilove, Janice L.
    Perez, Edith A.
    Tomita, Dianne K.
    Rossi, Greg
    Cleeland, Charles S.
    [J]. CANCER, 2007, 110 (07) : 1629 - 1640
  • [44] Application of a Module of the MD Anderson Symptom Inventory in Chinese Patient after Lung Cancer Surgery (MDASI-LC)
    Tang, Li
    Yu, Hongfan
    Xu, Wei
    Wang, Yaqin
    Liao, Jia
    Dai, Wei
    Wang, Xin Shelley
    Shi, Qiuling
    [J]. QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S124 - S125
  • [45] Validity and utility of the University of Texas M. D. Anderson Symptom Inventory (MDASI) among prostate cancer patients: Data from E2Z02: Symptom Outcomes and Practice Patterns (SOAPP).
    Patrick-Miller, Linda J.
    Zhao, Fengmin
    Cleeland, Charles S.
    Wagner, Lynne I.
    Fisch, Michael
    Mendoza, Tito R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Validation of the Swedish M. D. Anderson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer and Neurologic Swallowing Disturbances
    Carlsson, Sigrid
    Ryden, Anna
    Rudberg, Ingrid
    Bove, Mogens
    Bergquist, Henrik
    Finizia, Caterina
    [J]. DYSPHAGIA, 2012, 27 (03) : 361 - 369
  • [47] Validation of the Swedish M. D. Anderson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer and Neurologic Swallowing Disturbances
    Sigrid Carlsson
    Anna Rydén
    Ingrid Rudberg
    Mogens Bove
    Henrik Bergquist
    Caterina Finizia
    [J]. Dysphagia, 2012, 27 : 361 - 369
  • [48] Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
    Loretta A. Williams
    Meagan S. Whisenant
    Tito R. Mendoza
    Angela E. Peek
    Donna Malveaux
    Donna K. Griffin
    Darcy A. Ponce
    Bruno Palma Granwehr
    Ajay Sheshadri
    Katherine A. Hutcheson
    Sara M. Ali
    Susan K. Peterson
    John V. Heymach
    Charles S. Cleeland
    Ishwaria M. Subbiah
    [J]. Journal of Patient-Reported Outcomes, 7
  • [49] Symptom assessment in patients with chronic lymphocytic leukemia: Validation and application of the M.D. Anderson Symptom Inventory.
    Wang, XS
    Ferrajoli, A
    Broadway, JB
    Mobley, GM
    Mendoza, TR
    Keating, MJ
    Cleeland, C
    [J]. BLOOD, 2005, 106 (11) : 331B - 331B
  • [50] Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
    Williams, Loretta A.
    Whisenant, Meagan S.
    Mendoza, Tito R.
    Peek, Angela E.
    Malveaux, Donna
    Griffin, Donna K.
    Ponce, Darcy A.
    Granwehr, Bruno Palma
    Sheshadri, Ajay
    Hutcheson, Katherine A.
    Ali, Sara M.
    Peterson, Susan K.
    Heymach, John V.
    Cleeland, Charles S.
    Subbiah, Ishwaria M.
    [J]. JOURNAL OF PATIENT-REPORTED OUTCOMES, 2023, 7 (01)